Rapamycin is a medicine that has long been used to suppress the immune system, for example following organ transplants. In recent years it has also been receiving attention for its potential benefits in slowing down the ageing process. This is because rapamycin helps cells to maintain themselves better by stimulating a natural clearance process, similar to the effects of a low-calorie diet.
In mice, rapamycin extends lifespan by about 20 to 25 percent, which is a major effect compared to calorie restriction alone. In humans, the effect is less well studied and the drug is sometimes already prescribed off-label – that is, outside of its official indication – by anti-ageing doctors. However, the optimal dosage for slowing down ageing remains unknown and there are questions about potential side effects, such as a weakened immune system or higher blood sugar levels.
To gain more clarity, a new academic study has recently been launched testing rapamycin at various dosages in humans. The aim is not only to determine which dosage works best, but also which is safe in the long term. This is important because the drug has been around for some time and is now available in generic form, meaning pharmaceutical companies have fewer incentives to fund large clinical trials.
For people interested in healthy ageing, this research offers hope. It could lead to reliable information on safe applications of rapamycin that can slow down the ageing process without unnecessary risks.
Source: Reason
